#1 Clinical Trials Search in Europe

Evaluating the effect of semaglutide on wound healing in patients with diabetic foot ulcers

1 1 1 1

What is this study about?

This study aims to evaluate the effect of semaglutide on the time it takes for wounds to close in individuals living with a diabetic foot ulcer. A diabetic foot ulcer is an open sore or wound located on the foot that is caused by complications related to diabetes. Participants will receive either semaglutide or the standard medical care currently used to treat these wounds.

The medication semaglutide is administered through a subcutaneous injection, which is a method of delivering medicine into the fatty layer of tissue just beneath the skin. During the course of the study, the size and depth of the wounds will be monitored, and the healing process will be observed over a period of time to determine how effectively the treatment works compared to standard treatments.

Who Can Join the Study?

  • You must have type 2 diabetes mellitus, which is a long-term condition that affects how your body processes blood sugar.
  • You must have an active diabetic foot ulcer, which is an open sore or wound on the foot caused by diabetes that is currently present.
  • You must be older than 18 years of age.
  • You must be able to communicate well in either Dutch or English.

Who Cannot Join the Study?

  • People who are currently using or have used a GLP-1RA or GLP-1/GIP co-agonist (types of medications used to manage blood sugar) within the last 6 months.
  • Anyone with an allergy (an extreme immune system reaction) to any of the ingredients found in the semaglutide injections.
  • People who are currently pregnant.
  • Anyone who has previously had pancreatitis (inflammation of the pancreas, an organ behind the stomach) that was caused by using GLP-1RA medications.
  • People with end-stage renal disease, which means the kidneys are no longer working properly; this is defined as having an estimated GFR (a measure of how well the kidneys filter blood) of less than 15 or needing renal replacement therapy (such as dialysis to clean the blood).
  • People currently using anti-inflammatory therapy, such as prednisolone (a type of medicine used to reduce swelling and inflammation in the body).
  • People whose life expectancy (expected remaining lifespan) is less than 3 months.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

No sites found in this category

Other Sites

Site Name City Country Status
Stichting Radboud University Medical Center Nijmegen The Netherlands

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
The Netherlands The Netherlands
Not yet recruiting
01.01.2026

Trial locations

Investigated drugs:

Semaglutide is a medication given as a shot under the skin to help study its effect on how quickly diabetic foot wounds can heal and close.

Diabetic foot ulcer – This condition involves a break in the skin on the foot of an individual with diabetes. It often begins as a small sore or blister that fails to heal properly. The progression can involve the wound increasing in surface area or depth over time. Poor blood flow and nerve damage in the feet often contribute to how the wound develops. As it worsens, the area may become more deeply affected by skin breakdown.

Trial ID:
2025-524738-24-00
Protocol code:
R0126321A
Trial Phase:
Therapeutic confirmatory (Phase III)

Other Trials to Consider

  • Study on the Effect of Semaglutide on Healing Foot Ulcers in Patients with Type 2 Diabetes

    Recruiting

    1 1
    Investigated drugs:
    Denmark

  • Study on the Effects of Autologous Bone Marrow-Derived Mononuclear Cells for Patients with Diabetic Foot Syndrome and Lower Limb Ischemia

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Czechia